Palisade Bio wins FDA IND clearance for PALI-2108 Crohn’s disease Phase 2 trial
PALI•FDA clears IND for Phase 2 Crohn’s study
Palisade Bio received FDA clearance of its IND for PALI-2108, enabling a Phase 2 trial in moderate to severe Crohn’s disease.
- ASCENTRA-CD is set to enroll about 60 patients; first dosing is targeted for Q1 2027.
- The primary efficacy readout is targeted for Q1 2028, based on Week 12 endoscopic response.
